董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Heinz Mausli | 男 | Independent Director | 63 | 11.86万美元 | 未持股 | 2026-01-01 |
| Gerard Ber | 男 | Independent Director | 68 | 11.29万美元 | 未持股 | 2026-01-01 |
| Julie H. McHugh | 女 | Lead Independent Director | 61 | 18.43万美元 | 未持股 | 2026-01-01 |
| Gary J. Pruden | 男 | Independent Director | 64 | 18.53万美元 | 未持股 | 2026-01-01 |
| James H. Thrall | 男 | Independent Director | 82 | 17.93万美元 | 未持股 | 2026-01-01 |
| Phuong Khanh Morrow | -- | Independent Director | -- | 未披露 | 未持股 | 2026-01-01 |
| Minnie V. Baylor Henry | -- | Independent Director | -- | 未披露 | 未持股 | 2026-01-01 |
| Julie M. Eastland | -- | Independent Director | -- | 未披露 | 未持股 | 2026-01-01 |
| Mary Anne Heino | 女 | Executive Chair and Interim Chief Executive Officer | 66 | 432.64万美元 | 未持股 | 2026-01-01 |
| Samuel Leno | 男 | Independent Director | 80 | 19.34万美元 | 未持股 | 2026-01-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert J. Marshall, Jr. | 男 | Chief Financial Officer and Treasurer | 59 | 132.46万美元 | 未持股 | 2026-01-01 |
| Kimberly Brown | -- | Chief Accounting Officer | -- | 未披露 | 未持股 | 2026-01-01 |
| Jamie Spaeth | -- | Chief People Officer | -- | 未披露 | 未持股 | 2026-01-01 |
| Daniel M. Niedzwiecki | -- | Chief Administrative Officer, General Counsel and Corporate Secretary | -- | 未披露 | 未持股 | 2026-01-01 |
| Jean Claude Provost | -- | Chief Science Officer | -- | 未披露 | 未持股 | 2026-01-01 |
| Amanda Morgan | 女 | Chief Commercial Officer | -- | 未披露 | 未持股 | 2026-01-01 |
| Mary Anne Heino | 女 | Executive Chair and Interim Chief Executive Officer | 66 | 432.64万美元 | 未持股 | 2026-01-01 |
董事简历
中英对照 | 中文 | 英文- Heinz Mausli
-
Heinz Mausli，现任首席财务官；2008-2014，担任本公司董事。他于2003年加入AAA。他还是AAA一些子公司的董事。加入AAA之前，1996-2001，他是Accenture的管理顾问；1995-1996，担任Gemini Consulting的管理顾问。1988年，他在瑞士St. Gallen的University of St. Gallen获得硕士学位；1994年，在纽约州纽约市Columbia Business School获得工商管理硕士学位。
Heinz Mausli is a Director and a member of the Audit Committee and Compensation Committee, serving on the Board of Directors since June 2020. He is also a member of the Board of Directors of Inventiva SA. He served on the Board of Directors and as the Chairperson of the Audit Committee of Progenics until its acquisition by the Company. Mr. Musli is the former Chief Financial Officer of Advanced Accelerator Applications S.A., previously serving on its board and also on the executive team that managed its integration into Novartis AG after helping it grow into a global leader within its field. Mr. Musli previously worked as a management consultant for a number of strategy projects in both Europe and the United States for Accenture and Gemini Consulting, as well as independently. - Heinz Mausli，现任首席财务官；2008-2014，担任本公司董事。他于2003年加入AAA。他还是AAA一些子公司的董事。加入AAA之前，1996-2001，他是Accenture的管理顾问；1995-1996，担任Gemini Consulting的管理顾问。1988年，他在瑞士St. Gallen的University of St. Gallen获得硕士学位；1994年，在纽约州纽约市Columbia Business School获得工商管理硕士学位。
- Heinz Mausli is a Director and a member of the Audit Committee and Compensation Committee, serving on the Board of Directors since June 2020. He is also a member of the Board of Directors of Inventiva SA. He served on the Board of Directors and as the Chairperson of the Audit Committee of Progenics until its acquisition by the Company. Mr. Musli is the former Chief Financial Officer of Advanced Accelerator Applications S.A., previously serving on its board and also on the executive team that managed its integration into Novartis AG after helping it grow into a global leader within its field. Mr. Musli previously worked as a management consultant for a number of strategy projects in both Europe and the United States for Accenture and Gemini Consulting, as well as independently.
- Gerard Ber
-
Gerard Ber，现任首席运营官；2002-2004，担任本公司董事。他于2002年加入AAA。此前，2000-2002，他是 OM Pharma的西欧地区总监；1994-2000，担任CIS Medipro的总监、营销与商务总监；1984-1994，在CIS Bio International担任过各种管理职务。他还是AAA一些子公司的董事。1983年，1984年，他在法国Grenoble的Université Scientifique et Médicale de Grenoble分别获得药剂学博士学位、食品高级研究硕士学位；1984年，在法国巴黎的Institut de Pharmacie Industrielle de Paris获得营销与国际商务学位。
Gerard Ber is a Director and a member of the Science and Technology Committee, serving on the Board since June 2020. Dr. Ber is also a member of the Board of Y-mAbs Therapeutics, Inc. He served on the Board of Directors of Progenics until its acquisition by the Company. Dr. Ber was also the Co-Founder and former Chief Operating Officer of Advanced Accelerator Applications S.A. until its acquisition by Novartis AG. - Gerard Ber，现任首席运营官；2002-2004，担任本公司董事。他于2002年加入AAA。此前，2000-2002，他是 OM Pharma的西欧地区总监；1994-2000，担任CIS Medipro的总监、营销与商务总监；1984-1994，在CIS Bio International担任过各种管理职务。他还是AAA一些子公司的董事。1983年，1984年，他在法国Grenoble的Université Scientifique et Médicale de Grenoble分别获得药剂学博士学位、食品高级研究硕士学位；1984年，在法国巴黎的Institut de Pharmacie Industrielle de Paris获得营销与国际商务学位。
- Gerard Ber is a Director and a member of the Science and Technology Committee, serving on the Board since June 2020. Dr. Ber is also a member of the Board of Y-mAbs Therapeutics, Inc. He served on the Board of Directors of Progenics until its acquisition by the Company. Dr. Ber was also the Co-Founder and former Chief Operating Officer of Advanced Accelerator Applications S.A. until its acquisition by Novartis AG.
- Julie H. McHugh
-
Julie H. McHugh，她曾担任Lantheus Holdings， Inc.的成员。自2015年6月起担任董事会成员。她曾担任Endo Health Solutions， Inc.的首席运营官（2010年3月至2013年5月退休），负责专业制药和仿制药业务。在此之前，她是Nora Therapeutics， Inc.（一家风险资本支持的生物技术初创公司，专注于开发治疗不孕症的新疗法）的首席执行官。此前，她曾担任Johnson & Johnson全球病毒学业务部门的公司集团主席，在此之前，她曾担任强生子公司Centocor， Inc.的总裁。在此职位上，她负责监督几种产品的开发和发布，包括Remicade infliximab， Prezista （darunavir）和intelligence （etravirine）。加入Centocor之前，她在Astra-Merck Inc.领导胃肠药物Prilosec（奥美拉唑）的营销传播。她目前担任Ironwood Pharmaceuticals， Inc.的董事会主席，以及Lantheus Holdings， Inc.、New Xellia Group A/S和Trevena Pharmaceuticals， Inc.的董事会成员。她曾担任the Biotechnology Industry Organization （BIO）、the New England Healthcare Institute （NEHI）、the Pennsylvania Biotechnology Association、EPIRUS Biopharmaceuticals, Inc.和ViroPharma Inc.的董事会成员。她在St. Joseph大学获得工商管理硕士学位，在Pennsylvania State大学获得学士学位。
Julie H. McHugh,most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from 2010 through 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses.Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc.Before that she served as company group chair for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade (infliximab) and she was responsible for oversight of a research and development portfolio including compounds targeting autoimmune diseases, HIV, hepatitis C, and tuberculosis.Prior to joining Centocor, Inc., Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc.Ms. McHugh currently serves on the board of directors of Lantheus Holdings, Inc. (Nasdaq: LNTH), a public company, and Xellia Pharmaceuticals ApS, a privately held company. She also serves on the strategic advisory board for HealthCare Royalty Partners and the board of visitors for the Smeal College of Business of Pennsylvania State University. She previously served on the board of directors for Aerie Pharmaceuticals, Inc., Trevena, Inc., ViroPharma Inc., Epirus Biopharmaceuticals, Inc., Evelo Biosciences, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute.Ms. McHugh received her M.B.A. degree from St. Joseph's University and her B.S. degree from Pennsylvania State University. - Julie H. McHugh，她曾担任Lantheus Holdings， Inc.的成员。自2015年6月起担任董事会成员。她曾担任Endo Health Solutions， Inc.的首席运营官（2010年3月至2013年5月退休），负责专业制药和仿制药业务。在此之前，她是Nora Therapeutics， Inc.（一家风险资本支持的生物技术初创公司，专注于开发治疗不孕症的新疗法）的首席执行官。此前，她曾担任Johnson & Johnson全球病毒学业务部门的公司集团主席，在此之前，她曾担任强生子公司Centocor， Inc.的总裁。在此职位上，她负责监督几种产品的开发和发布，包括Remicade infliximab， Prezista （darunavir）和intelligence （etravirine）。加入Centocor之前，她在Astra-Merck Inc.领导胃肠药物Prilosec（奥美拉唑）的营销传播。她目前担任Ironwood Pharmaceuticals， Inc.的董事会主席，以及Lantheus Holdings， Inc.、New Xellia Group A/S和Trevena Pharmaceuticals， Inc.的董事会成员。她曾担任the Biotechnology Industry Organization （BIO）、the New England Healthcare Institute （NEHI）、the Pennsylvania Biotechnology Association、EPIRUS Biopharmaceuticals, Inc.和ViroPharma Inc.的董事会成员。她在St. Joseph大学获得工商管理硕士学位，在Pennsylvania State大学获得学士学位。
- Julie H. McHugh,most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from 2010 through 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses.Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc.Before that she served as company group chair for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade (infliximab) and she was responsible for oversight of a research and development portfolio including compounds targeting autoimmune diseases, HIV, hepatitis C, and tuberculosis.Prior to joining Centocor, Inc., Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc.Ms. McHugh currently serves on the board of directors of Lantheus Holdings, Inc. (Nasdaq: LNTH), a public company, and Xellia Pharmaceuticals ApS, a privately held company. She also serves on the strategic advisory board for HealthCare Royalty Partners and the board of visitors for the Smeal College of Business of Pennsylvania State University. She previously served on the board of directors for Aerie Pharmaceuticals, Inc., Trevena, Inc., ViroPharma Inc., Epirus Biopharmaceuticals, Inc., Evelo Biosciences, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute.Ms. McHugh received her M.B.A. degree from St. Joseph's University and her B.S. degree from Pennsylvania State University.
- Gary J. Pruden
-
GaryJ.Pruden是董事，审计委员会和薪酬委员会成员，自2018年2月起在董事会任职。Pruden先生在全球梦百合行业有着30多年的经验。最近，Pruden先生于1985年至2017年在强生的医疗器械和制药部门担任了多个高级商业领导职位。2016年4月，普鲁登先生被任命为强生公司执行委员会成员，他的正式头衔是执行Vice President，全球医疗器械董事长。在此之前，他在强生公司担任越来越重要的职务，从2015年到2016年担任医疗器械部门的全球主席，从2012年到2015年担任全球外科集团的全球主席，从2012年到2015年担任Ethicon的公司集团主席，从2009年到2012年担任J&J子公司Ethicon，Inc.的全球总裁，从2006年到2009年担任J&J子公司加拿大Janssen-Ortho Inc.的总裁。Pruden先生还担任过多个职位，包括先进医疗技术协会（Advanced Medical Technology Association）的技术与监管委员会主席和执行委员会成员，该协会是一家医疗设备行业协会。Pruden先生目前担任Motus GiHoldings，Inc.的董事会成员、审计委员会和薪酬委员会成员、Ossio公司的董事会成员和审计委员会主席，以及Avisi Technologies公司的董事会成员。Pruden先生在莱德大学（Rider University）获得金融理学学士学位，在那里他后来从2011年到2015年担任董事会成员。
Gary J. Pruden,has served on Motus Gi Holdings, Inc. Board since December 2017. Prior to joining Motus Gi Holdings, Inc. , from 1985 until 2017, Mr. Pruden held a number of senior commercial leadership positions across both the medical devices and pharmaceutical sectors of Johnson & Johnson (NYSE: JNJ). In April 2004, he became President of the Johnson & Johnson subsidiary, Janssen-Ortho Inc. in Canada. In January 2006, Mr. Pruden was appointed Worldwide President of Ethicon, Inc., a Johnson & Johnson subsidiary, and in 2009 became the Company Group Chairman of Ethicon, Inc. In 2012, he was named Worldwide Chairman of Johnson & Johnson's Global Surgery Group and in 2015 he became Worldwide Chairman in the Medical Devices division. In April 2016, Mr. Pruden became a member of the Executive Committee at Johnson & Johnson where his official title was Executive Vice President, Worldwide Chairman, Medical Devices. Mr. Pruden also served in several capacities with the Advanced Medical Technology Association (AdvaMed), a medical device trade association, where he participated in negotiations with the FDA. While at AdvaMed Mr. Pruden served as a member of the board of directors, as chair of the AdvaMed Regulatory Committee, and as a member of the AdvaMed Executive Committee. Mr. Pruden serves as an independent board member for Lantheus Holdings, Inc. (NASDAQ: LNTH) (and serves as a member of its Audit committee and the chair of its Compensation committee), OSSIO Inc, (and serves as the chair of its Audit committee) and Avisi Technologies Inc. Mr. Pruden received his B.S. degree in finance at Rider University, where he later served on the Board of Trustees from 2011 until 2015. - GaryJ.Pruden是董事，审计委员会和薪酬委员会成员，自2018年2月起在董事会任职。Pruden先生在全球梦百合行业有着30多年的经验。最近，Pruden先生于1985年至2017年在强生的医疗器械和制药部门担任了多个高级商业领导职位。2016年4月，普鲁登先生被任命为强生公司执行委员会成员，他的正式头衔是执行Vice President，全球医疗器械董事长。在此之前，他在强生公司担任越来越重要的职务，从2015年到2016年担任医疗器械部门的全球主席，从2012年到2015年担任全球外科集团的全球主席，从2012年到2015年担任Ethicon的公司集团主席，从2009年到2012年担任J&J子公司Ethicon，Inc.的全球总裁，从2006年到2009年担任J&J子公司加拿大Janssen-Ortho Inc.的总裁。Pruden先生还担任过多个职位，包括先进医疗技术协会（Advanced Medical Technology Association）的技术与监管委员会主席和执行委员会成员，该协会是一家医疗设备行业协会。Pruden先生目前担任Motus GiHoldings，Inc.的董事会成员、审计委员会和薪酬委员会成员、Ossio公司的董事会成员和审计委员会主席，以及Avisi Technologies公司的董事会成员。Pruden先生在莱德大学（Rider University）获得金融理学学士学位，在那里他后来从2011年到2015年担任董事会成员。
- Gary J. Pruden,has served on Motus Gi Holdings, Inc. Board since December 2017. Prior to joining Motus Gi Holdings, Inc. , from 1985 until 2017, Mr. Pruden held a number of senior commercial leadership positions across both the medical devices and pharmaceutical sectors of Johnson & Johnson (NYSE: JNJ). In April 2004, he became President of the Johnson & Johnson subsidiary, Janssen-Ortho Inc. in Canada. In January 2006, Mr. Pruden was appointed Worldwide President of Ethicon, Inc., a Johnson & Johnson subsidiary, and in 2009 became the Company Group Chairman of Ethicon, Inc. In 2012, he was named Worldwide Chairman of Johnson & Johnson's Global Surgery Group and in 2015 he became Worldwide Chairman in the Medical Devices division. In April 2016, Mr. Pruden became a member of the Executive Committee at Johnson & Johnson where his official title was Executive Vice President, Worldwide Chairman, Medical Devices. Mr. Pruden also served in several capacities with the Advanced Medical Technology Association (AdvaMed), a medical device trade association, where he participated in negotiations with the FDA. While at AdvaMed Mr. Pruden served as a member of the board of directors, as chair of the AdvaMed Regulatory Committee, and as a member of the AdvaMed Executive Committee. Mr. Pruden serves as an independent board member for Lantheus Holdings, Inc. (NASDAQ: LNTH) (and serves as a member of its Audit committee and the chair of its Compensation committee), OSSIO Inc, (and serves as the chair of its Audit committee) and Avisi Technologies Inc. Mr. Pruden received his B.S. degree in finance at Rider University, where he later served on the Board of Trustees from 2011 until 2015.
- James H. Thrall
-
James H.Thrall自2018年2月起担任董事，提名和公司治理委员会成员以及科学和技术委员会主席。Thrall博士目前在哈佛医学院（Harvard Medical School）担任杰出的Juan M.Taveras放射学教授，并从1988年到2013年担任马萨诸塞州总医院放射学系主任。在此之前，萨尔博士在1983年至1988年期间担任亨利福特医院放射学主席，在那里他还担任医生受托人，并担任亨利福特医务人员Vice Chairman of the Board。Thrall博士是美国国家医学研究院（National Academy of Medicine）的成员，曾在许多美国和国际医学和专业协会担任领导和董事会职位。Thall博士于1968年在密歇根大学（University of Michigan）获得医学博士学位，并在华盛顿特区沃尔特·里德陆军医学中心（Walter Reed Army Medical Center）接受放射学和核医学培训。
James H. Thrall is a Director, a member of the Nominating and Corporate Governance Committee and the Chairperson of the Science and Technology Committee, serving on the Board since February 2018. Dr. Thrall currently holds the Distinguished Juan M. Taveras Professorship of Radiology at Harvard Medical School, having also served as Chairman of the Department of Radiology at the Massachusetts General Hospital from 1988 until 2013. Previously, Dr. Thrall served as Chairman of Radiology at the Henry Ford Hospital between 1983 and 1988 where he also served as a Physician Trustee and held the position of Vice Chairman of the Board of Governors of the Henry Ford Medical Staff. Dr. Thrall is a member of the National Academy of Medicine and has served in leadership and board of directors positions at many U.S. and international medical and professional societies. Dr. Thrall received his M.D. from the University of Michigan in 1968 and trained in Radiology and Nuclear Medicine at the Walter Reed Army Medical Center, Washington, D.C. Dr. Thrall returned to the University of Michigan in 1975 and was promoted to Professor in 1981. - James H.Thrall自2018年2月起担任董事，提名和公司治理委员会成员以及科学和技术委员会主席。Thrall博士目前在哈佛医学院（Harvard Medical School）担任杰出的Juan M.Taveras放射学教授，并从1988年到2013年担任马萨诸塞州总医院放射学系主任。在此之前，萨尔博士在1983年至1988年期间担任亨利福特医院放射学主席，在那里他还担任医生受托人，并担任亨利福特医务人员Vice Chairman of the Board。Thrall博士是美国国家医学研究院（National Academy of Medicine）的成员，曾在许多美国和国际医学和专业协会担任领导和董事会职位。Thall博士于1968年在密歇根大学（University of Michigan）获得医学博士学位，并在华盛顿特区沃尔特·里德陆军医学中心（Walter Reed Army Medical Center）接受放射学和核医学培训。
- James H. Thrall is a Director, a member of the Nominating and Corporate Governance Committee and the Chairperson of the Science and Technology Committee, serving on the Board since February 2018. Dr. Thrall currently holds the Distinguished Juan M. Taveras Professorship of Radiology at Harvard Medical School, having also served as Chairman of the Department of Radiology at the Massachusetts General Hospital from 1988 until 2013. Previously, Dr. Thrall served as Chairman of Radiology at the Henry Ford Hospital between 1983 and 1988 where he also served as a Physician Trustee and held the position of Vice Chairman of the Board of Governors of the Henry Ford Medical Staff. Dr. Thrall is a member of the National Academy of Medicine and has served in leadership and board of directors positions at many U.S. and international medical and professional societies. Dr. Thrall received his M.D. from the University of Michigan in 1968 and trained in Radiology and Nuclear Medicine at the Walter Reed Army Medical Center, Washington, D.C. Dr. Thrall returned to the University of Michigan in 1975 and was promoted to Professor in 1981.
- Phuong Khanh Morrow
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Minnie V. Baylor Henry
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Julie M. Eastland
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Mary Anne Heino
-
Mary Anne Heino自2015年8月起担任Lantheus Holdings， Inc.的总裁兼首席执行官和董事。她曾担任Lantheus Holdings， Inc.的首席运营官（从2015年3月到2015年8月），以及Lantheus Holdings， Inc.的首席商务官（从2013年4月加入公司到2015年3月）。在加入Lantheus之前，她从2007年2月到2012年3月领导Angelini Labopharm LLC和Labopharm USA担任全球销售和营销总裁和高级副总裁。从2000年5月到2007年2月，她曾担任Centocor， Inc.（强生公司）的多个职位。她于1989年6月在Janssen pharmaceuticals（另一家强生公司）开始了她的职业生涯，并于1999年晋升为现场销售总监。她持有the Stern School of Business at New York大学的工商管理硕士学位。她获得了New York City大学New York的护理学学士学位和New York State大学at Stony Brook的生物学学士学位。她目前担任Massachusetts Business Roundtable执行委员会和MassMEDIC董事会成员。
Mary Anne Heino has served as Lantheus Holdings, Inc.'s President and Chief Executive Officer and as a Director since August 2015. She previously served as Lantheus Holdings, Inc.'s Chief Operating Officer, a position she held from March 2015 until August 2015 and as Lantheus Holdings, Inc.'s Chief Commercial Officer, a position she held from April 2013 when she joined the Company until March 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012. From May 2000 until February 2007 Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson ("J&J") company. Ms. Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master in Business Administration from the Stern School of Business at New York University. She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor of Science in Biology from the State University of New York at Stony Brook. Ms. Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC. - Mary Anne Heino自2015年8月起担任Lantheus Holdings， Inc.的总裁兼首席执行官和董事。她曾担任Lantheus Holdings， Inc.的首席运营官（从2015年3月到2015年8月），以及Lantheus Holdings， Inc.的首席商务官（从2013年4月加入公司到2015年3月）。在加入Lantheus之前，她从2007年2月到2012年3月领导Angelini Labopharm LLC和Labopharm USA担任全球销售和营销总裁和高级副总裁。从2000年5月到2007年2月，她曾担任Centocor， Inc.（强生公司）的多个职位。她于1989年6月在Janssen pharmaceuticals（另一家强生公司）开始了她的职业生涯，并于1999年晋升为现场销售总监。她持有the Stern School of Business at New York大学的工商管理硕士学位。她获得了New York City大学New York的护理学学士学位和New York State大学at Stony Brook的生物学学士学位。她目前担任Massachusetts Business Roundtable执行委员会和MassMEDIC董事会成员。
- Mary Anne Heino has served as Lantheus Holdings, Inc.'s President and Chief Executive Officer and as a Director since August 2015. She previously served as Lantheus Holdings, Inc.'s Chief Operating Officer, a position she held from March 2015 until August 2015 and as Lantheus Holdings, Inc.'s Chief Commercial Officer, a position she held from April 2013 when she joined the Company until March 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012. From May 2000 until February 2007 Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson ("J&J") company. Ms. Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master in Business Administration from the Stern School of Business at New York University. She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor of Science in Biology from the State University of New York at Stony Brook. Ms. Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC.
- Samuel Leno
-
Samuel Leno是董事，审计委员会主席，提名和公司治理委员会成员，自2012年5月起在董事会任职。Leno先生是一位战略执行官，在复杂的跨国公司拥有超过40年的经验。他最近担任Boston Scientific的执行Vice President和首席运营官。他此前曾担任执行Vice President、财务和信息系统以及首席财务官。他于2011年12月退任Boston Scientific公司。加入Boston Scientific公司之前，雷诺先生曾担任齐默尔控股公司（Zimmer Holdings，Inc.）的执行Vice President、财务和企业服务及首席财务官，以及ArrowElectronics，Inc.、企业Express，Inc.和Coram梦百合的首席财务官职位。此前，他曾担任Baxter International，Inc.、American Hospital Supply Corporation的多种高级财务职务。他曾是Zest Anchors，Inc.的董事会主席和审计委员会主席。他此前曾任职Omnicare公司和Tomotherapy公司的董事会和审计委员会，也曾任职Endotronix公司的董事会。Leno先生曾在美国海军担任中尉，是一名越南老兵。他持有Northern Illinois University的会计理学学士学位，以及Roosevelt University的工商管理硕士学位。
Samuel Leno is a Director and the Chairperson of the Audit Committee and a member of the Nominating and Corporate Governance Committee, serving on the Board since May 2012. Mr. Leno is a strategic executive with more than 40 years of experience with complex multinational companies. He most recently held the positions of Executive Vice President and Chief Operations Officer at Boston Scientific. He previously served as Executive Vice President, Finance and Information Systems and Chief Financial Officer. He retired from Boston Scientific in December 2011. Prior to joining Boston Scientific, Mr. Leno served as Executive Vice President, Finance and Corporate Services and Chief Financial Officer at Zimmer Holdings, Inc. and Chief Financial Officer positions at Arrow Electronics, Inc., Corporate Express, Inc. and Coram Healthcare. Previously, he held a variety of senior financial positions at Baxter International, Inc. and American Hospital Supply Corporation. He was the Chairman of the Board of Directors and of the Audit Committee of Zest Anchors, Inc. He previously served on the Boards of Directors and the Audit Committees of Omnicare and TomoTherapy, Inc. and also served on the Board of Directors of Endotronix, Inc. Mr. Leno served as a Lieutenant in the United States Navy and is a Vietnam veteran. He holds a Bachelor of Science in Accounting from Northern Illinois University and a Master of Business Administration from Roosevelt University. - Samuel Leno是董事，审计委员会主席，提名和公司治理委员会成员，自2012年5月起在董事会任职。Leno先生是一位战略执行官，在复杂的跨国公司拥有超过40年的经验。他最近担任Boston Scientific的执行Vice President和首席运营官。他此前曾担任执行Vice President、财务和信息系统以及首席财务官。他于2011年12月退任Boston Scientific公司。加入Boston Scientific公司之前，雷诺先生曾担任齐默尔控股公司（Zimmer Holdings，Inc.）的执行Vice President、财务和企业服务及首席财务官，以及ArrowElectronics，Inc.、企业Express，Inc.和Coram梦百合的首席财务官职位。此前，他曾担任Baxter International，Inc.、American Hospital Supply Corporation的多种高级财务职务。他曾是Zest Anchors，Inc.的董事会主席和审计委员会主席。他此前曾任职Omnicare公司和Tomotherapy公司的董事会和审计委员会，也曾任职Endotronix公司的董事会。Leno先生曾在美国海军担任中尉，是一名越南老兵。他持有Northern Illinois University的会计理学学士学位，以及Roosevelt University的工商管理硕士学位。
- Samuel Leno is a Director and the Chairperson of the Audit Committee and a member of the Nominating and Corporate Governance Committee, serving on the Board since May 2012. Mr. Leno is a strategic executive with more than 40 years of experience with complex multinational companies. He most recently held the positions of Executive Vice President and Chief Operations Officer at Boston Scientific. He previously served as Executive Vice President, Finance and Information Systems and Chief Financial Officer. He retired from Boston Scientific in December 2011. Prior to joining Boston Scientific, Mr. Leno served as Executive Vice President, Finance and Corporate Services and Chief Financial Officer at Zimmer Holdings, Inc. and Chief Financial Officer positions at Arrow Electronics, Inc., Corporate Express, Inc. and Coram Healthcare. Previously, he held a variety of senior financial positions at Baxter International, Inc. and American Hospital Supply Corporation. He was the Chairman of the Board of Directors and of the Audit Committee of Zest Anchors, Inc. He previously served on the Boards of Directors and the Audit Committees of Omnicare and TomoTherapy, Inc. and also served on the Board of Directors of Endotronix, Inc. Mr. Leno served as a Lieutenant in the United States Navy and is a Vietnam veteran. He holds a Bachelor of Science in Accounting from Northern Illinois University and a Master of Business Administration from Roosevelt University.
高管简历
中英对照 | 中文 | 英文- Robert J. Marshall, Jr.
Robert J.Marshall，Jr.于2018年9月加入Lantheus，担任首席财务官兼财务主管。在加入Lantheus之前，Marshall先生在齐默巴奥米特控股公司公司工作了16年，该公司是一家在肌肉骨骼健康方面处于领先地位的全球性医疗设备公司。他曾担任多种高级领导职务，包括Vice President、投资者关系和公司财务主管，最近担任美国、加拿大和拉丁美洲商业市场的美洲金融Vice President。任职Zimmer Biomet公司之前，他曾任职Brown&Williamson Tobacco公司（British American Tobacco，P.L.C.的子公司，位于肯塔基州路易斯维尔），在那里他曾担任多种职务，并不断被提拔。Marshall先生持有南本德印第安纳大学（Indiana University，South Bend）的工商管理硕士学位，以及圣母大学（University of Notre Dame）的金融学工商管理学士学位。他还持有CFA称号。
Robert J. Marshall, Jr. joined Lantheus as Chief Financial Officer and Treasurer in September 2018. Prior to joining Lantheus, Mr. Marshall spent 16 years with Zimmer Biomet Holdings, Inc., a global medical device company with a leading position in musculoskeletal health. He held various senior leadership roles, including Vice President, Investor Relations and Corporate Treasurer, and most recently as Vice President, Americas Finance, for the U.S., Canadian and Latin American commercial markets. Prior to Zimmer Biomet, Mr. Marshall was employed with Brown & Williamson Tobacco, a subsidiary of British American Tobacco, p.l.c., in Louisville, Kentucky, where he held several positions of increasing responsibility. Mr. Marshall holds a Master of Business Administration from Indiana University, South Bend, and a Bachelor of Business Administration in Finance from the University of Notre Dame. He also holds the CFA designation.- Robert J.Marshall，Jr.于2018年9月加入Lantheus，担任首席财务官兼财务主管。在加入Lantheus之前，Marshall先生在齐默巴奥米特控股公司公司工作了16年，该公司是一家在肌肉骨骼健康方面处于领先地位的全球性医疗设备公司。他曾担任多种高级领导职务，包括Vice President、投资者关系和公司财务主管，最近担任美国、加拿大和拉丁美洲商业市场的美洲金融Vice President。任职Zimmer Biomet公司之前，他曾任职Brown&Williamson Tobacco公司（British American Tobacco，P.L.C.的子公司，位于肯塔基州路易斯维尔），在那里他曾担任多种职务，并不断被提拔。Marshall先生持有南本德印第安纳大学（Indiana University，South Bend）的工商管理硕士学位，以及圣母大学（University of Notre Dame）的金融学工商管理学士学位。他还持有CFA称号。
- Robert J. Marshall, Jr. joined Lantheus as Chief Financial Officer and Treasurer in September 2018. Prior to joining Lantheus, Mr. Marshall spent 16 years with Zimmer Biomet Holdings, Inc., a global medical device company with a leading position in musculoskeletal health. He held various senior leadership roles, including Vice President, Investor Relations and Corporate Treasurer, and most recently as Vice President, Americas Finance, for the U.S., Canadian and Latin American commercial markets. Prior to Zimmer Biomet, Mr. Marshall was employed with Brown & Williamson Tobacco, a subsidiary of British American Tobacco, p.l.c., in Louisville, Kentucky, where he held several positions of increasing responsibility. Mr. Marshall holds a Master of Business Administration from Indiana University, South Bend, and a Bachelor of Business Administration in Finance from the University of Notre Dame. He also holds the CFA designation.
- Kimberly Brown
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jamie Spaeth
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Daniel M. Niedzwiecki
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jean Claude Provost
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Amanda Morgan
Amanda Morgan，于2022年11月加入Lantheus，担任商务高级副总裁，并晋升为首席商务官，2024年3月25日生效。Morgan女士是一位在医疗保健行业拥有超20年经验的高管，Morgan女士是一位经验丰富的商业领袖。在加入Lantheus之前，她是阿卡迪亚的首席营收和客户官，在那里她成功地领导了这家商业机构。在加入Acadia之前，Morgan女士曾在Shire plc担任逐渐具有挑战性的职务，包括美国销售主管和美国患者服务主管，为数十亿美元的制药企业提供支持。Morgan女士拥有爱荷华大学工商管理学士学位。
Amanda Morgan,joined Lantheus in November 2022 as Senior Vice President, Commercial and was promoted to Chief Commercial Officer, effective March 25, 2024. Ms. Morgan is an executive with over 20 years of experience in the healthcare industry, Ms. Morgan is a seasoned commercial leader. Prior to joining Lantheus, she was Chief Revenue and Customer Officer at Acadia Pharmaceuticals, where she successfully led the commercial organization. Prior to her tenure at Acadia, Ms. Morgan held progressively challenging roles at Shire Plc, including U.S. Head of Sales and U.S. Head of Patient Services, supporting multi-billion-dollar pharmaceutical businesses. Ms. Morgan holds a Bachelor of Business Administration from The University of Iowa.- Amanda Morgan，于2022年11月加入Lantheus，担任商务高级副总裁，并晋升为首席商务官，2024年3月25日生效。Morgan女士是一位在医疗保健行业拥有超20年经验的高管，Morgan女士是一位经验丰富的商业领袖。在加入Lantheus之前，她是阿卡迪亚的首席营收和客户官，在那里她成功地领导了这家商业机构。在加入Acadia之前，Morgan女士曾在Shire plc担任逐渐具有挑战性的职务，包括美国销售主管和美国患者服务主管，为数十亿美元的制药企业提供支持。Morgan女士拥有爱荷华大学工商管理学士学位。
- Amanda Morgan,joined Lantheus in November 2022 as Senior Vice President, Commercial and was promoted to Chief Commercial Officer, effective March 25, 2024. Ms. Morgan is an executive with over 20 years of experience in the healthcare industry, Ms. Morgan is a seasoned commercial leader. Prior to joining Lantheus, she was Chief Revenue and Customer Officer at Acadia Pharmaceuticals, where she successfully led the commercial organization. Prior to her tenure at Acadia, Ms. Morgan held progressively challenging roles at Shire Plc, including U.S. Head of Sales and U.S. Head of Patient Services, supporting multi-billion-dollar pharmaceutical businesses. Ms. Morgan holds a Bachelor of Business Administration from The University of Iowa.
- Mary Anne Heino
Mary Anne Heino自2015年8月起担任Lantheus Holdings， Inc.的总裁兼首席执行官和董事。她曾担任Lantheus Holdings， Inc.的首席运营官（从2015年3月到2015年8月），以及Lantheus Holdings， Inc.的首席商务官（从2013年4月加入公司到2015年3月）。在加入Lantheus之前，她从2007年2月到2012年3月领导Angelini Labopharm LLC和Labopharm USA担任全球销售和营销总裁和高级副总裁。从2000年5月到2007年2月，她曾担任Centocor， Inc.（强生公司）的多个职位。她于1989年6月在Janssen pharmaceuticals（另一家强生公司）开始了她的职业生涯，并于1999年晋升为现场销售总监。她持有the Stern School of Business at New York大学的工商管理硕士学位。她获得了New York City大学New York的护理学学士学位和New York State大学at Stony Brook的生物学学士学位。她目前担任Massachusetts Business Roundtable执行委员会和MassMEDIC董事会成员。
Mary Anne Heino has served as Lantheus Holdings, Inc.'s President and Chief Executive Officer and as a Director since August 2015. She previously served as Lantheus Holdings, Inc.'s Chief Operating Officer, a position she held from March 2015 until August 2015 and as Lantheus Holdings, Inc.'s Chief Commercial Officer, a position she held from April 2013 when she joined the Company until March 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012. From May 2000 until February 2007 Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson ("J&J") company. Ms. Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master in Business Administration from the Stern School of Business at New York University. She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor of Science in Biology from the State University of New York at Stony Brook. Ms. Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC.- Mary Anne Heino自2015年8月起担任Lantheus Holdings， Inc.的总裁兼首席执行官和董事。她曾担任Lantheus Holdings， Inc.的首席运营官（从2015年3月到2015年8月），以及Lantheus Holdings， Inc.的首席商务官（从2013年4月加入公司到2015年3月）。在加入Lantheus之前，她从2007年2月到2012年3月领导Angelini Labopharm LLC和Labopharm USA担任全球销售和营销总裁和高级副总裁。从2000年5月到2007年2月，她曾担任Centocor， Inc.（强生公司）的多个职位。她于1989年6月在Janssen pharmaceuticals（另一家强生公司）开始了她的职业生涯，并于1999年晋升为现场销售总监。她持有the Stern School of Business at New York大学的工商管理硕士学位。她获得了New York City大学New York的护理学学士学位和New York State大学at Stony Brook的生物学学士学位。她目前担任Massachusetts Business Roundtable执行委员会和MassMEDIC董事会成员。
- Mary Anne Heino has served as Lantheus Holdings, Inc.'s President and Chief Executive Officer and as a Director since August 2015. She previously served as Lantheus Holdings, Inc.'s Chief Operating Officer, a position she held from March 2015 until August 2015 and as Lantheus Holdings, Inc.'s Chief Commercial Officer, a position she held from April 2013 when she joined the Company until March 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing from February 2007 to March 2012. From May 2000 until February 2007 Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson ("J&J") company. Ms. Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master in Business Administration from the Stern School of Business at New York University. She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor of Science in Biology from the State University of New York at Stony Brook. Ms. Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC.